Compare Neurocrine Biosciences Inc (NBIX) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs S&P500 ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while S&P500 ETF trades at $763.24. The key difference: S&P500 ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SPY | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | — |
52-Week High | $185.50 | $777.82 |
52-Week Low | $123.10 | $631.99 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SPY trades at $766.00, down 0.55% on the day, with a neutral technical signal and bullish moving averages. Support levels are near $760, while resistance sits at $769. The ETF shows no available valuation ratios like P/E or P/B in the data. A dividend of $1.90 is scheduled for payment on July 31, 2026.
Outlook remains mixed amid market volatility from geopolitical tensions and oil price surges. Risks include Fed rate-hike concerns and high valuations, but AI-driven earnings growth offers potential upside. Investors should weigh resilience against near-term headwinds for long-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
